Search company, investor...

Predict your next investment

Corporate Venture
FINANCE | Investment Firms & Funds
leaps.bayer.com

Investments

65

Portfolio Exits

6

Partners & Customers

1

About Leaps by Bayer

Leaps by Bayer is a research institution in the healthcare and agriculture sector.

Headquarters Location

Kaiser-Wilhelm-Allee 1

Nordrhein-Westfalen, 51368,

Germany

Want to inform investors similar to Leaps by Bayer about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Research containing Leaps by Bayer

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Leaps by Bayer in 1 CB Insights research brief, most recently on Aug 8, 2023.

Latest Leaps by Bayer News

ReCode Therapeutics Raises Additional $50M in Series B

Sep 20, 2023

September 20, 2023 ReCode Therapeutics , a Menlo Park, CA-based clinical-stage genetic medicines company using precision delivery mRNA and gene correction therapeutics, closed an extension to its Series B financing, raising an additional $50m, for a total of $260m. Backers included new backers Bioluminescence Ventures and Solasta Ventures, and existing investors including OrbiMed Advisors, AyurMaya, an affiliate of Matrix Capital Management, Leaps by Bayer, Vida Ventures, MPM Capital, Pfizer Ventures, EcoR1 Capital, Sanofi Ventures and Amgen Ventures, Osage University Partners (OUP), among others. Kouki Harasaki, Ph.D., founding and managing partner of Bioluminescence Ventures (BLV), joined the company’s board of directors. The company intends to use the funds to advance its primary ciliary dyskinesia and cystic fibrosis clinical development programs and to expand its proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) pipeline to include mRNA and gene correction therapeutics for central nervous system, lung, liver and musculoskeletal indications. Led by Shehnaaz Suliman, M.D., MBA, M.Phil., chief executive officer, ReCode Therapeutics is a clinical-stage genetic medicines company using precision delivery to power mRNA and gene correction therapeutics. Its Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform enables precise and targeted delivery of genetic medicines directly to the organs and cells implicated in disease, enabling improved efficacy and potency. Its lead programs include RCT1100 for the treatment of primary ciliary dyskinesia caused by pathogenic mutations in the DNAI1 gene, and RCT2100 for the treatment of the 10-13 percent of cystic fibrosis patients who have Class I mutations in the CFTR gene and do not respond to currently approved CFTR modulators. RCT1100 and RCT2100 are inhaled disease-modifying mRNA-based therapies formulated using the SORT LNP delivery platform. ReCode is expanding its pipeline to develop potential therapies for other rare and common genetic diseases including musculoskeletal, central nervous system, liver and infectious disease indications.

Leaps by Bayer Investments

65 Investments

Leaps by Bayer has made 65 investments. Their latest investment was in Mozart Therapeutics as part of their Series A - II on June 6, 2023.

CBI Logo

Leaps by Bayer Investments Activity

investments chart

Leaps by Bayer Portfolio Exits

6 Portfolio Exits

Leaps by Bayer has 6 portfolio exits. Their latest portfolio exit was Azitra on June 16, 2023.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/16/2023

IPO

$99M

Public

4

8/1/2022

Corporate Majority

Subscribe to see more

$99M

Subscribe to see more

10

12/20/2021

Acq - Pending

Subscribe to see more

$99M

Subscribe to see more

10

10/8/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

6/21/2021

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/16/2023

8/1/2022

12/20/2021

10/8/2021

6/21/2021

Exit

IPO

Corporate Majority

Acq - Pending

IPO

IPO

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Public

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

4

10

10

10

10

Leaps by Bayer Partners & Customers

1 Partners and customers

Leaps by Bayer has 1 strategic partners and customers. Leaps by Bayer recently partnered with Temasek on August 8, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

8/12/2020

Partner

Singapore

Bayer and Temasek team up to develop vegetable varieties for vertical farming

Unfold raised USD 30 million in the initial funding round and entered into an agreement for certain rights to germplasm from Bayer AG 's vegetable portfolio .

2

Date

8/12/2020

Type

Partner

Business Partner

Country

Singapore

News Snippet

Bayer and Temasek team up to develop vegetable varieties for vertical farming

Unfold raised USD 30 million in the initial funding round and entered into an agreement for certain rights to germplasm from Bayer AG 's vegetable portfolio .

Sources

2

Leaps by Bayer Team

8 Team Members

Leaps by Bayer has 8 team members, including current Executive Vice President, Jürgen Eckhardt.

Name

Work History

Title

Status

Jürgen Eckhardt

Executive Vice President

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Jürgen Eckhardt

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

Executive Vice President

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.